Accordingly, the stock price of the company’s shares decreases ... ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...

Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead candidate, CM24, for treating pancreatic ductal adenocarcinoma (“PDAC ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Shares of Purple Biotech Ltd (NASDAQ:PPBT ... The stock had previously closed at $4.69. Separately, HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

An announcement from Purple Biotech ( (PPBT) ) is now available.